---

Elderly Male with Pacemaker: Acute SOB + AKI + ALI - ADHF vs Acute-on-CKD Evaluation & Management

Clinical Context

• Known complete heart block with permanent pacemaker (PPM)
• Acute onset dyspnea / shortness of breath (SOB)
• Acute Kidney Injury (AKI)
• Acute Lung Injury (ALI) / pulmonary edema
• Primary differential: ADHF (Cardiorenal Syndrome type 1) vs Acute-on-CKD with fluid overload

---

Step 1: Initial Rapid Assessment (First 30-60 minutes)

A. Hemodynamic Profile - "Wet vs Dry / Cold vs Warm"

• Most ADHF presentations are Warm & Wet (elevated filling pressures, adequate perfusion)
• Cold & Wet = most severe - requires urgent inotropic support

B. Rapid Bedside Assessment

---

Step 2: Pacemaker-Specific Considerations

1. Pacemaker interrogation is mandatory - Check for:
   • Mode switch events (indicating AF burden)
   • Rate-responsive function (may mask tachycardia)
   • Pacing threshold changes (electrode dislodgement or lead failure)
   • Impedance trends (lead insulation breach)
   • Stored electrograms - episodes of fast AF, VT
2. Pacemaker-Induced Cardiomyopathy (PICM):
   • Occurs in ~20% of patients with chronic RV pacing
   • Causes dyssynchrony - LVEF drops, can precipitate ADHF
   • Look for LBBB morphology on ECG/paced beats
   • If pacing burden >40% over years, suspect PICM
3. Pacemaker syndrome (in VVI devices):
   • VA conduction causes retrograde P-waves, symptoms of low output
4. Device infection - Consider if fever + sepsis contribution to AKI
5. ECG: Will show paced rhythm; compare with prior ECG for changes in morphology

---

Step 3: Key Investigations

A. Immediate (Bedside/Emergency)

B. Laboratory - Priority

C. BNP/NT-proBNP Interpretation

• BNP >100 pg/mL or NT-proBNP >300 pg/mL = Supports HF diagnosis (Class I ACC/AHA recommendation)
• NT-proBNP age-adjusted cut-offs: <75 yrs: >125 pg/mL; >75 yrs: >450 pg/mL (higher with AKI/CKD - interpret cautiously)
• BNP <35 or NT-proBNP <125: Makes ADHF unlikely
• Caveat: Both are elevated in CKD independent of HF - use relative levels and clinical correlation

Note: "BNP and NT-proBNP are similar for diagnosis of AHF, but NT-proBNP is superior in predicting clinical outcome." - Fuster and Hurst's The Heart, 15th Ed.

D. Echocardiography (Formal, urgent)

• LVEF: HFrEF (<40%) vs HFpEF (≥50%)
• RWMA - Regional wall motion abnormalities (ACS precipitant)
• Diastolic function - E/e' ratio - elevated in HFpEF
• RV function - Cor pulmonale from chronic lung disease
• Pericardial effusion - Tamponade causing low output
• Lead position - Right ventricular lead position
• Valvular disease - TR, MR (functional) worsening

---

Step 4: Cardiorenal Syndrome Classification

"At least five subtypes of cardiorenal syndrome have been proposed. Worsening renal function in heart failure is not the same as acute kidney injury (AKI) in heart failure." - Brenner & Rector's The Kidney

• Reduced cardiac output → Reduced renal blood flow (RBF) → Prerenal AKI
• Elevated CVP → Elevated renal venous pressure → Reduced GFR (even without reduced RBF) - this is often underappreciated
• RAAS/SNS activation → Vasoconstriction → Oliguria

"Higher CVP was an important predictor of worsening renal function in acute HF" - Brenner & Rector's The Kidney

---

Step 5: ADHF vs Acute-on-CKD - Differentiating

---

Step 6: Management

A. Immediate Stabilization

1. Positioning: Head of bed 45°, legs dependent (reduces preload, eases breathing)
2. Oxygen: Target SpO2 92-96%; avoid hyperoxia
   • Non-invasive ventilation (NIV/BiPAP): If SpO2 <90% or respiratory distress despite O2 - reduces intubation, reduces preload, improves oxygenation
   • Reserve intubation for failure of NIV
3. IV access + monitoring: Continuous ECG, BP q15-30 min, urine output hourly
4. Hold nephrotoxins: NSAIDs, aminoglycosides, contrast (if avoidable), ACE inhibitors/ARBs temporarily if K >5.5 or creatinine rising rapidly

B. Decongestion - Core of ADHF Management

"After initial stabilization, the mainstay of treatment is vasodilator and diuretic therapy." - Brenner & Rector's The Kidney

• Target urine output: 100-200 mL/hour in first few hours
• Diuretic resistance (common in CRS): Furosemide response is blunted in HF due to rightward/downward shift of dose-response curve
  • Add thiazide (metolazone 2.5-5 mg PO 30 min before loop diuretic) for sequential nephron blockade
  • Increase IV dose; consider continuous infusion
  • Consider aldosterone antagonist addition
• Monitor: Creatinine, BUN, electrolytes q8-12h; tolerate creatinine rise up to ~0.3 mg/dL if congestion is improving ("aggressive decongestion associated with improved survival" even when creatinine worsens - Brenner & Rector)

• IV Nitroglycerin: Start at 5-10 mcg/min, titrate up - reduces preload rapidly; useful for acute pulmonary edema
• Nitroprusside: For severe hypertensive ADHF
• Nesiritide: Recombinant BNP; vasodilator + mild natriuretic effect; not shown to improve mortality

C. Pacemaker Management in ADHF

1. Urgent pacemaker interrogation
2. If PICM suspected (LVEF drop + high RV pacing burden):
   • Upgrade to CRT-D (Cardiac Resynchronization Therapy with Defibrillator) - this is the key intervention
   • Reduces dyssynchrony, improves LVEF, reduces HF hospitalizations
3. If pacemaker-dependent and hemodynamically unstable: Ensure programming is appropriate (rate-response on, avoid very slow programmed rates)
4. Check for device-related infection as AKI precipitant

D. Managing AKI in the Context of ADHF

1. Establish if prerenal vs intrinsic AKI:
   • FENa <1% + response to decongestion = prerenal (most common in ADHF)
   • Rising creatinine despite adequate decongestion = intrinsic/ATN
2. Do NOT reflexively hold diuretics - aggressive decongestion improves renal perfusion by reducing CVP
3. RAAS inhibitors: Hold ACEi/ARB temporarily if K >5.5 or creatinine rising >50% from baseline; restart at lower dose once stable
4. Monitor for hyperkalemia - ECG changes (peaked T waves, wide QRS) - requires urgent treatment
5. Dialysis indications: Refractory fluid overload, hyperkalemia unresponsive to medical management, severe acidosis (pH <7.1), uremic symptoms
6. Ultrafiltration: An option for diuretic-resistant fluid overload - recent meta-analysis (2024) shows better clinical decongestion than IV loop diuretics but no mortality benefit; higher risk of adverse events - reserve for refractory cases

E. Precipitant Identification and Treatment

• New AF (very common) - Rate control; anticoagulation with DOAC (dose-adjust for eGFR)
• ACS - Troponin elevation, RWMA on echo; urgent PCI if STEMI/NSTEMI
• Infection/sepsis - Procalcitonin, cultures, antibiotics
• Medication non-compliance - History critical
• Dietary salt indiscretion - Common trigger
• Drug culprits (NSAIDs, verapamil, diltiazem, contrast) - Review medication list

F. Pacemaker Patient - Special Drug Considerations

G. Monitoring & Goals of Therapy

• Daily weight (target 0.5-1 kg/day weight loss while decongesting)
• Strict fluid balance - aim for negative balance initially
• Creatinine/electrolytes q12h
• BNP/NT-proBNP at 24-48h - trends guide decongestion adequacy
• Repeat echo at 48-72h - track LVEF, IVC, diastolic function
• Pacemaker check formal report

---

Step 7: ADHF vs Acute-on-CKD - Summary Algorithm

Elderly male + PPM + Acute SOB + AKI + ALI
        ↓
1. ABG, SpO2, ECG, CXR, POCUS within 15 min
2. BNP/NT-proBNP + Troponin + RFT + Urine analysis
        ↓
BNP >300 + Echo: EF↓ or DD + Bilateral B-lines (POCUS)?
        ↓YES                    ↓NO
    ADHF (CRS)          Acute-on-CKD (consider infection,
    Diurese + vasodilate  NSAIDs, obstruction, ATN)
        ↓
Pacemaker interrogation
        ↓
PICM present? → CRT upgrade
AF present? → Rate control + anticoagulation
ACS? → PCI
        ↓
Daily monitoring: Weight, Cr, K+, BNP trend
Hold nephrotoxins; adjust diuretics for response

---

Key Points Summary

1. Classify CRS type - this patient likely has CRS Type 1 or 2 (cardiac primary, renal secondary)
2. Pacemaker interrogation is non-negotiable - must rule out PICM, device arrhythmia, and lead issues
3. BNP/NT-proBNP is the diagnostic anchor for ADHF; interpret in context of CKD (falsely elevated)
4. Aggressive IV diuresis is the cornerstone of ADHF management - do not be deterred by mild creatinine rise
5. Elevated CVP harms the kidney via venous congestion - decongestion itself improves renal function
6. Hold nephrotoxins and dose-adjust renally cleared drugs (digoxin, DOACs, spironolactone)
7. NIV/BiPAP for ALI/respiratory failure - reduces intubation need
8. CRT upgrade if PICM confirmed - most impactful intervention for ADHF from pacemaker-induced dyssynchrony
9. Recent (2026) meta-analysis on ARNi in ADHF supports angiotensin-neprilysin inhibition post-stabilization

---

Elderly Male + Pacemaker (Heart Block) | Acute SOB | AKI | ALI

Rule Out: ADHF vs Acute-on-CKD

---

OVERVIEW OF THE CLINICAL PROBLEM

"The interplay between heart and kidney is key to the pathophysiologic processes that occur in HF and end-stage renal disease, and the synergistic failure of both organs together has been termed cardiorenal syndrome." - Brenner & Rector's The Kidney

---

PART 1: SYSTEMATIC EVALUATION

A. Immediate Bedside Assessment (First 15 Minutes)

• Warm & Wet: IV diuretics + vasodilators
• Cold & Wet: Inotropes + cautious diuresis (this is the dangerous group)

---

B. History - Key Points in This Patient

---

C. Physical Examination - Targeted Findings

---

D. Investigations - Priority Ladder

STAT (Arrive in ≤30 min)

URGENT (2-4 hours)

INTERPRETIVE GUIDE - NT-proBNP / BNP

"When clinical signs and symptoms strongly support ADHF, the diagnosis can be made with high probability even in the absence of additional testing. For dyspneic patients with intermediate probability, the addition of serum natriuretic peptide testing is warranted." - Murray & Nadel's Respiratory Medicine

"BNP and NT-proBNP are similar for diagnosis of AHF, but NT-proBNP is superior in predicting clinical outcome." - Fuster & Hurst's The Heart, 15th Ed.

---

E. Pacemaker-Specific Evaluation (Non-Negotiable)

• Occurs in ~20% of patients with chronic RV-only pacing
• Mechanism: RV pacing creates left bundle branch block (LBBB) morphology → dyssynchronous LV contraction → LVEF drop over months-years
• Suspect when: LVEF <50%, high cumulative RV pacing burden, no other structural cause of HF
• ECG: Wide paced QRS with LBBB pattern
• Treatment: Upgrade to CRT (Cardiac Resynchronization Therapy) - resynchronizes LV contraction, dramatically improves LVEF

---

F. Key Differentiating Features: ADHF vs Acute-on-CKD

---

PART 2: PATHOPHYSIOLOGY (Understanding the CRS)

1. Reduced Cardiac Output pathway: Low CO → reduced renal blood flow → prerenal AKI → FENa <1%
2. Elevated CVP / Venous Congestion pathway (often underappreciated):
   • High CVP → elevated renal venous pressure → reduces glomerular perfusion pressure (MAP - Renal Venous Pressure)
   • Also: elevated renal interstitial pressure → raised Bowman capsule pressure → reduced GFR
   • This is RBF-independent AKI - the kidney is being strangled from the venous side

"Higher CVP was an important predictor of worsening renal function in acute HF, whereas CVP was also the strongest independent factor associated with eGFR in a large heterogeneous cardiovascular population." - Brenner & Rector's The Kidney

---

PART 3: MANAGEMENT

A. Immediate Stabilization (First Hour)

---

B. Decongestion - The Core Treatment

"After initial stabilization, the mainstay of treatment is vasodilator and diuretic therapy." - Brenner & Rector's The Kidney

• Target: Urine output 100-200 mL/hour in first 1-3 hours
• Dose titration: Re-assess at 1-2h; if UO <50 mL/hr, double the dose
• Continuous infusion vs bolus: No significant difference shown in DOSE trial; bolus dosing is acceptable
• Monitor: Creatinine, BUN, K+, Na+ q8-12h

1. Sequential nephron blockade: Add oral metolazone 2.5-5 mg PO 30-60 min before IV loop diuretic - blocks distal tubule and synergizes; monitor K+ closely
2. Switch to torsemide or bumetanide if on furosemide (more predictable kinetics)
3. Continuous IV infusion of loop diuretic
4. Add low-dose aldosterone antagonist (spironolactone 12.5-25 mg if K+ <5.0)

---

C. Pacemaker-Specific Management

1. Formal device interrogation (same day)
2. If PICM identified (LVEF drop + high RV pacing burden + LBBB morphology):
   • Upgrade to CRT-D (Cardiac Resynchronization Therapy - Defibrillator): restores LV dyssynchrony, dramatically improves LVEF, reduces HF hospitalizations and mortality
   • This is the single most impactful intervention for pacing-induced HF
3. If new AF detected on interrogation:
   • Rate control: IV metoprolol or amiodarone (if LVEF low, avoid non-dihydropyridine CCBs)
   • Anticoagulation: DOAC - dose-adjust for eGFR (apixaban preferred in renal impairment)
4. If ACS triggered decompensation: Urgent cardiology review, PCI if indicated
5. Rule out device pocket infection - if suspected, blood cultures, wound swab; device explant may be needed
6. Do NOT place central line or pacemaker lead on same side as existing device without cardiology guidance

---

D. Managing AKI in the Context of ADHF

• Do NOT reflexively hold diuretics when creatinine rises: aggressive decongestion reduces CVP, improves renal perfusion, and improves survival even with transient creatinine rise
• Tolerate creatinine rise up to ~0.3-0.5 mg/dL if congestion is clearing and urine output is maintained
• RAAS inhibitors (ACEi/ARB): hold temporarily if K+ >5.5 or creatinine rises >50% from baseline; restart at lower dose once stable - do NOT permanently stop
• Avoid hyperkalemia - monitor K+ q6-8h; give calcium gluconate for ECG changes; insulin-dextrose for acute K+ >6.5
• Indications for urgent dialysis/CRRT:
  • Refractory hyperkalemia (K+ >6.5 unresponsive to medical treatment)
  • Refractory pulmonary edema (no response to IV diuretics + ultrafiltration)
  • Severe metabolic acidosis (pH <7.1)
  • Uremic encephalopathy or pericarditis

• Better clinical decongestion than IV loop diuretics per 2024 meta-analysis (PMID 37469222)
• Does NOT improve re-hospitalization or mortality
• Higher risk of adverse events (catheter-related)
• Reserve for truly diuretic-refractory cases

---

E. ALI Management (Cardiogenic Pulmonary Edema)

1. Upright positioning + NIV/BiPAP
2. IV loop diuretics (reduce pulmonary venous pressure rapidly)
3. IV nitrates (immediate preload reduction - venodilation precedes diuresis)
4. If hypotensive + pulmonary edema = cardiogenic shock → dobutamine or milrinone (cautious inotropic support)

---

F. Inotropes - When and Which

"IV inotropes dobutamine and milrinone are reserved for situations in which ADHF is complicated by unresponsiveness to standard therapies, diminished peripheral perfusion, end-organ dysfunction, and/or hypotension (low-output syndrome)." - Brenner & Rector's The Kidney

---

G. Drug Adjustments in This Patient (Elderly + AKI + PPM)

---

H. Monitoring Goals During Admission

---

DECISION ALGORITHM

ELDERLY MALE + PACEMAKER + ACUTE SOB + AKI + ALI
              ↓
    ┌─────────────────────────────────┐
    │  IMMEDIATE (0-15 min)           │
    │  ABG, ECG, CXR, POCUS           │
    │  Sit up, O2/BiPAP               │
    └─────────────────────────────────┘
              ↓
    NT-proBNP + Troponin + BNP
    + Creatinine (compare baseline)
    + Echo (LVEF, IVC, B-lines)
              ↓
    ┌──────────────────────┬──────────────────────────┐
    │  ADHF (CRS Type 1)   │  Acute-on-CKD primary    │
    │  BNP high, EF low,   │  Prior CKD, normal echo, │
    │  B-lines+, IVC full  │  urinary casts, nephrotoxin│
    └──────────────────────┴──────────────────────────┘
              ↓
    PACEMAKER INTERROGATION
              ↓
    ┌──────────────────────────────────┐
    │ PICM? → CRT-D upgrade            │
    │ New AF? → Rate control + DOAC    │
    │ ACS? → Cardiology / PCI          │
    │ Sepsis? → Cultures + antibiotics │
    └──────────────────────────────────┘
              ↓
    IV DIURETICS + IV NITRATES
    (Warm & Wet: diurese + vasodilate)
    (Cold & Wet: inotrope + cautious diuresis)
              ↓
    Daily: Weight, Cr, K+, NT-proBNP trend
    Restart RAAS/BBlocker when stable
    Transition to oral diuretics when euvolemic

---

SUMMARY OF KEY PRINCIPLES

1. Classify hemodynamic profile first (Warm/Cold × Wet/Dry) - guides initial therapy
2. Pacemaker interrogation is non-negotiable - PICM, AF, lead failure must be excluded
3. NT-proBNP is the diagnostic anchor for ADHF; interpret with caution in CKD (falsely elevated) - trend matters more than a single value
4. Elevated CVP damages the kidney from the venous side - decongestion is renoprotective even when creatinine transiently rises
5. IV torsemide or bumetanide preferred over furosemide in HF+CKD (more predictable kinetics, less diuretic resistance)
6. Sequential nephron blockade (metolazone + loop diuretic) for diuretic-resistant cases
7. NIV/BiPAP for cardiogenic ALI - reduces intubation rates
8. Hold nephrotoxins (NSAIDs, contrast, aminoglycosides); temporarily hold RAAS inhibitors if AKI is worsening
9. Dialysis/CRRT if refractory hyperkalemia, fluid overload, acidosis, or uremia
10. Post-stabilization: restart ACEi/ARB/ARNI (sacubitril-valsartan now supported by 2026 meta-analysis, PMID 40689605), beta-blocker, MRA; consider CRT-D if PICM; DOAC if AF

---